Etanercept biosimilar (Clover Biopharmaceuticals)

依那西普生物类似药（三叶草生物制药）

Report date: 2026/05/09 20:00:18

Base Information

Drug NameEtanercept biosimilar (Clover Biopharmaceuticals)
Drug Alias Name依那西普生物仿制药（三叶草生物制药）重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白（三叶草生物制药）SCB-808
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor α inhibitorsTumor necrosis factor β inhibitors
TargetsTumor necrosis factor αTumor necrosis factor β
Therapy Area/IndicationsArthritis, RheumatoidSpondylitis, Ankylosing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesClover Biopharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesClover Biopharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, RheumatoidSpondylitis, Ankylosing
Inactive IndicationsN/A

Other Information

ATC CodeL04AB01
Related LinksN/A